Zonisamide

Epilepsia

Volumn 40, Issue SUPPL. 5, 1999, Pages s23-s29

  Leppik, Ilo E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Efficacy; Epilepsy; New antiepileptic drug; Side effects; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID; ZONISAMIDE;

ANOREXIA; ATAXIA; CONFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; FATIGUE; GENERALIZED EPILEPSY; HUMAN; MYOCLONUS EPILEPSY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TERATOGENICITY; VERTIGO;

EID: 0032849039     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00916.x     Document Type: Review

References (54)

1. Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. Chem Pharmacol Bull 1972;24:632-43.
2. Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforsch 1980;30: 477-83.
3. Ito T, Hori M, Masuda Y, Yoshida K, Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile. Arzneimittelforsch 1980;30: 603-9.
4. Wada Y, Hasegawa H, Okuda H, Yamaguchi N. Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev 1990;12:206-10.
5. Hori M, Ito T, Yoshida K, Shimizu M. Effect of anticonvulsants on spiking activity induced by cortical freezing in cats. Epilepsia 1979;20:25-36.
6. Ito T, Hori M, Yoshida K, Shimizu M. Effect of anticonvulsants on experimental cortical epilepsy induced by tungstic acid gel in rats. Arch Int Pharmacodyn 1979;241:287-99.
7. Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia 1986;27:367-74.
8. Fromm GH, Shibuya T, Terrence CF. Effect of zonisamide (CI-912) on a synaptic system model. Epilepsia 1987;28:673-9.
9. Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995;1011.
10. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
11. Ito T, Yamaguchi T, Miyazaki H, et al. Pharmacokinetic studies of Ad-810, a new antiepileptic compound, phase I trials. Arzneimittelforsch 1982;32:1581-6.
12. 14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in man. Arzneimittelforsch 1983;33: 961-8.
13. Juergens U. Simultaneous determination of zonisamide and nine other antiepileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography. J Chromatogr 1987;385:233-40.
14. Furuno K, Oishi R, Gomita Y, Eto K. Simple and sensitive assay of zonisamide in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J Chromatogr [B] 1994;656:456-9.
15. Kaibe K, Nishimura S, Ishii H, Sunahara N, Naruto S, Kuraoka S. Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibody Clin Chem 1990;36:24-7.
16. Buchanan RA, Bockbrader HN, Chang T, Sedman AJ. Single- and multiple-dose pharmacokinetics of zonisamide [Abstract]. Epilepsia 1996;37(suppl 5):172.
17. Taylor CP, McLean JR, Bockbraer HN, et al. Zonisamide (AD-810, CI-912). In: Meldrum BS, Porter RJ, eds. New anticonvulsant drugs. London: John Libbey, 1986:277-94.
18. Page JG, Kochak GM, Polvino WJ, Buchanan RA. Multiple dose zonisamide metabolism [Abstract]. Epilepsia 37(suppl 5):172.
19. 14C]zonisamide in rat brain. Epilepsy Res 1994;17:223-6.
20. Stiff DD, Zemaitis MA. Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dis 1990;18:888-94.
21. Sugihara K, Kitamura S, Tatsumi K. Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Disp 1996;24:199-202.
22. Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 1992;22:1-11.
23. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kitada M. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Disp 1993;21:777-81.
24. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 1993;44:216-21.
25. Nakasa H, Ohmori S, Kitada M. Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes. Xenobiotica 1996;26:495-501.
26. Nakasa H, Komiya M, Ohmori S, Kitada M, Rikihisa T, Kanakubo Y. Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes. Res Commun Chem Pathol Pharmacol 1992;77:31-41.
27. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. Pharmacokinetic interaction of zonisamide in rats: effect of other antiepileptics on zonisamide. J Pharmacobiol Dyn 1992;15:631-9.
28. Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol Pharmacol Bull 1996;19:1090-2.
29. Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986;8: 293-6.
30. Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Asved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985;26:206-11.
31. McJilton J, DeToledo J, DeCerce J, Huda S, Abubakr A, Ramsay RE. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels [Abstract]. Epilepsia 1996;37(suppl 5):173.
32. Wagner JG, Sackellares JC, Donofrio PD, Berent S, Sakmer E. Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984;6:277-83.
33. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharmacol Bull 1994; 17:323-6.
34. Matsumoto K, Miyazaki H, Fujii T, Miyazaki H, Hashimoto M. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction. Chem Pharmacol Bull 1989;37:2807-10.
35. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics. Biol Pharmacol Bull 1993;16:722-5.
36. Kaneko S, Hayashimoto A, Niwayama H, Fukushima Y. Effects of zonisamide on serum levels of phenytoin and carbamazepine. Jpn J Epilepsy Soc 1993;11:31-5 (in Japanese).
37. Tasaki K, Minami T, Ieiri I, et al. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995;17:182-5.
38. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia 1985;26:212-20.
39. Wilder BJ, Ramsay RE, Guterman A, et al. A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of Dainippon Pharmaceutical Co., Ltd., 1986.
40. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epielpsy: a European double blind trial. Epilepsy Res 1993;15:67-73.
41. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of znoisamide: results of a multicenter study. Epilepsy Res 1993;14: 165-73.
42. Browne TR, Leppik IE, Penry JK, Dean C, Buchanan RA. Zonisamide efficacy in long term studies. Epilepsia 1997;38(suppl 8):108.
43. Kumagai N, Seki T, Yamawaki H, et al. Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatr Neurol 1991;45: 357-9.
44. Seino M, Miyazaki H, Ito T. Zonisamide. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs. Epilepsy Res Suppl 3. New York: Elsevier, 1997:169-74.
45. Henry T, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1998;38:928-31.
46. Kyllerman M, Ben-Menachem E. Long-term treatment of progressive myoclonic epilepsy syndromes with zonisamide and n-acetylcysteine [Abstract]. Epilepsia 1996;37(suppl 5):172.
47. Yagi K, Seino M. Open clinical trial of new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures. Clin Psychiatry 1992;29:111-9 (in Japanese).
48. Yamatogi Y, Ohtahara S. Current topics of treatment. In: Ohtahara S, Roger J, eds. Proceedings of the international symposium, New Trends in Pediatric Epileptology. Okayama U Med School 1991;136-48.
49. Padgett CS, Bergen DC, French JA, Buchanan RA. Renal calculi associated with zonisamide [Abstract]. Epilepsia 37(suppl 5):173.
50. Berent S, Sackellares JC, Giordani B, Wagner JG, Donofrio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987;28:61-7.
51. Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 1990;31:214-7.
52. Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia 1994;35:403-5.
53. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37:1242-4.
54. Naito H, Itoh N, Matsui N, Eguchi T. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 1988;43: 463-7.